Deciphex secures $32.3M Series C to address global pathology shortage
Deciphex has closed its Series C financing, raising $32.3 million to address the acute global pathology crisis.
Led by Molten Ventures with significant participation from ACT Venture Capital, Seroba, Charles River Laboratories, IRRUS Investments, HBAN Medtech Syndicate and Nextsteps Capital, the funding will advance Deciphex's mission to democratize access to high-quality pathology through a technology-enabled global network of pathologists.
With over 70% of healthcare decisions requiring pathology investigation and a widening gap between rising patient needs and declining pathologist numbers, healthcare systems face mounting backlogs globally. Deciphex's platforms, Diagnexia and Patholytix, address this crisis through AI-powered digital pathology that enables pathologists to work up to 40% faster while maintaining diagnostic accuracy.
This funding round considerably advances Deciphex's strategic priorities:
- Scaling global service reach
- Enhancing utility of Diagnexia and Patholytix platforms
- Accelerating pathology AI foundational model development
- Strengthening partnerships with industry leaders
- Expand services to pharma/ biotech and CRO clients
